Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis

BMC Ophthalmology

Research Article

Jeremy P. Howell¹  Mario Bittner¹  Martin K. Schmid¹  Sophie C. Böhni¹  Livia Faes²  Lucas M. Bachmann² 

[1] Eye Clinic, Cantonal Hospital of Lucerne, Spitalstrasse, 6000, Lucerne 16, Switzerland;Medignition Inc. Research Consultants, Zurich, Switzerland;

关键词: Optical Coherence Tomography;    Ranibizumab;    Well Correct Visual Acuity;    Aflibercept;    Early Treatment Diabetic Retinopathy Study;   

DOI  :  10.1186/s12886-015-0101-4

 received in 2015-01-09, accepted in 2015-08-04,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTo identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting.MethodsWe compared two groups of patients with a fairly similar prognosis either receiving Aflibercept or Ranibizumab within a pro re nata regimen for 1 year. Changes in visual acuity (letters) and central foveal thickness (CFT) and frequency of injections after completing the loading phase were evaluated using two separate multivariate mixed linear models.ResultsWhen correcting for baseline differences between the Aflibercept (11 eyes) and Ranibizumab (16 eyes) group, there was neither divergence in visual acuity (−0.97 letters (95 % CI. −6.06-4.12); p = 0.709), nor a significant difference in the reduction of CFT (−25.16 μm, 95 % CI; (−78.01-27.68); p = 0.351) between the two groups 1 year after treatment initiation. Also, the number of injection did not differ (0.04 (95 % CI; −0.16-0.09); p = 0.565).ConclusionIn contrast to health claims, treatment-naïve nvAMD, Ranibizumab and Aflibercept were equivalent in terms of functional and morphologic outcomes and number of injections when studied in real-life clinical practice.

【 授权许可】

CC BY   
© Böhni et al. 2015